MA52412A - Nouveaux composés sulfonimidoylpurinone substitués en position 7 et dérivés pour le traitement et la prophylaxie du cancer du foie - Google Patents

Nouveaux composés sulfonimidoylpurinone substitués en position 7 et dérivés pour le traitement et la prophylaxie du cancer du foie

Info

Publication number
MA52412A
MA52412A MA052412A MA52412A MA52412A MA 52412 A MA52412 A MA 52412A MA 052412 A MA052412 A MA 052412A MA 52412 A MA52412 A MA 52412A MA 52412 A MA52412 A MA 52412A
Authority
MA
Morocco
Prior art keywords
prophylaxis
derivatives
treatment
new
liver cancer
Prior art date
Application number
MA052412A
Other languages
English (en)
French (fr)
Inventor
Carina Hage
Sabine Hoves
Thomas Poeschinger
Carola Ries
Hong Shen
Hongying Yun
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA52412A publication Critical patent/MA52412A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MA052412A 2018-02-28 2019-02-26 Nouveaux composés sulfonimidoylpurinone substitués en position 7 et dérivés pour le traitement et la prophylaxie du cancer du foie MA52412A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2018077501 2018-02-28

Publications (1)

Publication Number Publication Date
MA52412A true MA52412A (fr) 2021-06-02

Family

ID=65685310

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052412A MA52412A (fr) 2018-02-28 2019-02-26 Nouveaux composés sulfonimidoylpurinone substitués en position 7 et dérivés pour le traitement et la prophylaxie du cancer du foie

Country Status (19)

Country Link
EP (1) EP3758707A1 (es)
JP (1) JP7089596B2 (es)
KR (1) KR20200128414A (es)
CN (1) CN111801100B (es)
AR (1) AR114419A1 (es)
AU (1) AU2019228654A1 (es)
BR (1) BR112020016509A2 (es)
CA (1) CA3091950A1 (es)
CL (1) CL2020002139A1 (es)
CO (1) CO2020010306A2 (es)
IL (1) IL276817A (es)
MA (1) MA52412A (es)
MX (1) MX2020008746A (es)
PE (1) PE20211456A1 (es)
PH (1) PH12020551343A1 (es)
RU (1) RU2020131012A (es)
SG (1) SG11202008291XA (es)
TW (1) TW202003518A (es)
WO (1) WO2019166432A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20170169A1 (ar) 2016-08-29 2019-01-30 Novartis Ag مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو
MX2020008959A (es) 2018-02-28 2020-10-05 Novartis Ag Derivados de 10-(di(fenil)metil)-4-hidroxi-8,9,9a,10-tetrahidro-7h -pirrolo[1',2':4,5]pirazino[1,2-b]piridazina-3,5-diona y compuestos relacionados como inhibidores de la replicacion del ortomixovirus para el tratamiento de influenza.
KR102409595B1 (ko) 2020-06-29 2022-06-17 한국과학기술연구원 단백질 카이네이즈 csf-1r 억제제로서의 신규 퓨리논 유도체
CN112420196A (zh) * 2020-11-20 2021-02-26 长沙市弘源心血管健康研究院 急性心肌梗死患者5年内生存率的预测方法和系统
CN119604517A (zh) * 2022-07-14 2025-03-11 豪夫迈·罗氏有限公司 用于治疗癌症的磷酰基嘌呤酮化合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4189048B2 (ja) 1997-12-26 2008-12-03 大日本住友製薬株式会社 複素環化合物
WO2010077613A1 (en) 2008-12-09 2010-07-08 Gilead Sciences, Inc. Modulators of toll-like receptors
JP5913093B2 (ja) * 2009-05-21 2016-04-27 アストラゼネカ アクチボラグ 新規ピリミジン誘導体と、癌とさらなる疾患の治療におけるそれらの使用
CN102666541B (zh) * 2009-10-22 2015-11-25 吉里德科学公司 用于治疗特别是病毒感染的嘌呤或脱氮嘌呤的衍生物
WO2011079016A1 (en) * 2009-12-22 2011-06-30 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
CA2802733C (en) * 2010-06-24 2017-11-21 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
TWI506035B (zh) * 2010-08-13 2015-11-01 Baylor Res Inst 以直接針對抗原呈現細胞之抗體的標靶佐劑為主之新穎疫苗佐劑
MX376761B (es) * 2015-05-08 2025-03-07 Hoffmann La Roche Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas.
CN108430515B (zh) 2015-10-29 2021-11-12 诺华股份有限公司 包含toll-样受体激动剂的抗体缀合物
KR102459155B1 (ko) * 2016-08-29 2022-10-28 에프. 호프만-라 로슈 아게 바이러스 감염의 치료 및 예방을 위한 7-치환된 설폰이미도일푸린온 화합물
PL3512556T3 (pl) * 2016-09-13 2021-12-27 F. Hoffmann-La Roche Ag Leczenie skojarzone agonistą TLR7 i inhibitorem składania kapsydu HBV

Also Published As

Publication number Publication date
PH12020551343A1 (en) 2021-06-21
RU2020131012A (ru) 2022-03-28
CL2020002139A1 (es) 2021-01-04
SG11202008291XA (en) 2020-09-29
BR112020016509A2 (pt) 2020-12-15
CO2020010306A2 (es) 2020-08-31
KR20200128414A (ko) 2020-11-12
PE20211456A1 (es) 2021-08-05
JP2021514972A (ja) 2021-06-17
JP7089596B2 (ja) 2022-06-22
MX2020008746A (es) 2020-09-28
EP3758707A1 (en) 2021-01-06
CA3091950A1 (en) 2019-09-06
WO2019166432A1 (en) 2019-09-06
AU2019228654A1 (en) 2020-09-03
TW202003518A (zh) 2020-01-16
CN111801100B (zh) 2023-10-24
AR114419A1 (es) 2020-09-02
CN111801100A (zh) 2020-10-20
IL276817A (en) 2020-10-29

Similar Documents

Publication Publication Date Title
MA52412A (fr) Nouveaux composés sulfonimidoylpurinone substitués en position 7 et dérivés pour le traitement et la prophylaxie du cancer du foie
EP3781564C0 (en) PYRIDAZINE DERIVATIVES FOR TREATING CANCER
EP3551185A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF CDK4 / 6 MEDIATED CANCER
MA56508A (fr) Inhibiteur d'egfr pour le traitement du cancer
EP3641829A4 (en) INTERFERON PRODRUG FOR TREATMENT OF CANCER
MA51200A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
MA43746A (fr) Dérivés de 2-cyanoisoindoline pour le traitement du cancer
MA56019A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
MA52873A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
MA49906A (fr) Acides aminés à chaîne ramifiée pour le traitement d'une maladie du foie
EP3890749A4 (en) CDK9 INHIBITORS AND POLYMORPHS THEREOF FOR USE AS CANCER TREATMENT AGENT
EP3634431A4 (en) THERAPEUTIC COMPOSITIONS AND METHODS OF TREATMENT FOR HEPATITIS B
MA52961A (fr) Compositions et procédés pour la réduction ou le traitement d'une inflammation
MA55093A (fr) Méthodes et compositions pour le traitement du cancer
EP3781584A4 (en) 4'-THIO-NUCLEOTIDE AND NUCLEOSIDE PRODRUGS FOR THE TREATMENT OF CANCER
EP4149547A4 (en) Compositions and methods for treating cancer
EP3541379A4 (en) COMPOSITIONS FOR THE TREATMENT OF HYPERTONIA
EP3773221A4 (en) TREATMENT OF HYDROCEPHALUS
EP3612214A4 (en) ENZYME REPLACEMENT THERAPY OPTIMIZATION FOR THE TREATMENT OF HOMOCYSTINURIA
EP3400942A4 (en) USE OF CHINOLIN DERIVATIVES FOR THE TREATMENT OF CANCER CANCER AND TREATMENT METHOD, PHARMACEUTICAL COMPOSITION AND KIT THEREFOR
EP3675858A4 (en) COMPOUNDS AND COMPOSITIONS FOR IRE1 INHIBITION
EP3817774A4 (en) COMPOSITIONS AND METHODS FOR LOCAL ADMINISTRATION OF PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CANCER
EP3893902A4 (en) MODELS AND METHODS OF TREATMENT OF SERRATED COLORECTAL CANCER
MA71734A (fr) Composés pour le traitement du cancer
EP3638287A4 (en) Methods and compositions for treating microbial inflammation